Quantcast

Latest Cytopathology Stories

2014-08-06 08:31:39

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its second quarter 2014 financial results will be released after close of market on Wednesday, August 13, 2014. Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The live webcast and subsequent replay may be accessed by...

2014-07-03 08:23:28

- Decisions to Cover Afirma for Use in Thyroid Cancer Diagnosis Bring Total Number of "Blues" Covered Lives to More than 10 Million - SOUTH SAN FRANCISCO, Calif., July 3, 2014 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that two Blue Cross Blue Shield (BCBS)-affiliated organizations, Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, have issued positive coverage policies for the company's...

2014-06-23 08:27:52

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today commented on preliminary American Thyroid Association (ATA) guidelines regarding the management of thyroid nodules, which the ATA previewed Friday in a satellite symposium at the ICE/ENDO 2014 meeting in Chicago. "We are very encouraged by these preliminary guidelines as we believe our Afirma® Gene Expression...

2014-06-18 08:28:28

SOUTH SAN FRANCISCO, Calif., June 18, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the JMP Securities 2014 Healthcare Conference on Wednesday, June 25, 2014 at 11:30 a.m. ET in New York. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live...

2014-06-16 08:28:00

SOUTH SAN FRANCISCO, Calif., June 16, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list, based on an employee survey of Bay Area companies. "We truly believe that our employees are our best asset and are honored to be recognized by the Bay Area News Group as a Top Workplace," said Bonnie H. Anderson,...

2014-06-03 08:31:46

SOUTH SAN FRANCISCO, Calif., June 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 William Blair Growth Stock Conference on Tuesday, June 10, 2014 at 12:10 p.m. CT in Chicago. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast...

2014-05-28 08:31:02

SOUTH SAN FRANCISCO, Calif., May 28, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 9 a.m. ET in New York. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to...

2014-05-20 12:33:47

Classifier shows promise for differentiating IPF from other interstitial lung diseases SOUTH SAN FRANCISCO, Calif., May 20, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of the first proof-of-concept data demonstrating the company's ability to develop a molecular classifier to differentiate interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and its histological hallmark, usual interstitial pneumonia (UIP). The data were...

2014-05-13 08:31:36

SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for...

2014-05-07 20:24:22

LONDON, May 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA - Test & Patients - Worldwidehttp://www.reportbuyer.com/pharma_healthcare/diagnostics/cervical_cancer_test_market_patients_pap_smear_hpv_dna_via_test_patients_worldwide.htmlCervical cancer is one of the deadliest cancers among woman all over the world. However in the past few decades, mortality from cervical cancer has...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related